Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322682 · ClinicalTrials.gov registry record · Phase 3
Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
A Phase 3 study, sponsored by Montreal Heart Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4,506
- Enrollment target
NCT04322682: Clinical Trial Phase 3 study, sponsored by Montreal Heart Institute.
NCT04322682 is a Phase 3 study that was terminated before completion, run by Montreal Heart Institute. The registered enrollment target is 4,506 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (484% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04322682, a Phase 3 study, was terminated before completion, sponsored by Montreal Heart Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4,506 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
Primary Outcome
The primary endpoint will be the composite of death or hospitalization due to COVID-19 infection in the 30 days following randomization.
Interventions
- DRUG Colchicine
- DRUG Placebo oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,506 participants |
| Start Date | 2020-03-23 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 3 |
Why NCT04322682 stopped before completion
NCT04322682 is an interventional study that assigns participants to a tested intervention. Its 4,506 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (484% higher).
The record links to 0 conditions, and to 2 interventions - of which Colchicine is the first listed.
NCT04322682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04322682 about?
NCT04322682 is a clinical study titled "Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)". This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criter...
What is the current status of trial NCT04322682?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4,506 participants. The study started on 2020-03-23. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT04322682?
The interventions under investigation include: Colchicine (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04322682?
This trial is sponsored by Montreal Heart Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04322682's enrollment target sits among peer trials
4,506 55th of 2000 higher than 1,946 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- NCT07207564 · 4,500 participants
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI